



## **Supplemental Data**

### **Functional characterization of core components of the *Bacillus subtilis* c-di-GMP signaling pathway**


Xiaohui Gao<sup>1,3</sup>, Sampriti Mukherjee<sup>2</sup>, Paige M. Matthews<sup>1</sup>, Loubna A. Hammad<sup>1</sup>, Daniel B. Kearns<sup>2</sup>, Charles E. Dann III<sup>1\*</sup>, Department of Chemistry<sup>1</sup>, Department of Biology<sup>2</sup> and Biochemistry Graduate Program<sup>3</sup> Indiana University, Bloomington, IN 47405-7102




**FIG. S1. *In vivo* analysis of c-di-GMP production by putative DGCs in inducible expression strains derived from wild type *B. subtilis*.** All signals obtained from MRM transitions  $m/z$  691 → 152 (red),  $m/z$  691 → 540 (blue) and  $m/z$  691 → 248 (black) via LC-MS/MS are displayed for (A) c-di-GMP standard and bacterial extracts of (B) wild type *B. subtilis* and strains expressing putative DGCs: (C) YdaK, (D) DgcK (E) DgcP, and (F) DgcW. Transitions  $m/z$  691 → 152 (red),  $m/z$  691 → 540 (blue) are not unique to c-di-GMP in *B. subtilis* lysates. Only two transitions are shown in insets to indicate relative abundance of the unique identifier ( $m/z$  691 → 248 in black) and the most abundant fragmentation product ( $m/z$  691 → 152 in red).



**FIG. S2. *In vivo* analysis of c-di-GMP production by putative DGCs in a background lacking all endogenous DGCs.** All signals obtained from MRM transitions  $m/z$  691  $\rightarrow$  152 (red),  $m/z$  691  $\rightarrow$  540 (blue) and  $m/z$  691  $\rightarrow$  248 (black) via LC-MS/MS are displayed for (A) c-di-GMP standard and bacterial extracts of (B)  $\Delta ydaK\ dgcK\ dgcW\ dgcP :: tet$  *B. subtilis* - labeled as mutant - and strains expressing putative DGCs: (C) YdaK, (D) DgcK (E) DgcP, and (F) DgcW. Transitions  $m/z$  691  $\rightarrow$  152 (red),  $m/z$  691  $\rightarrow$  540 (blue) are not unique to c-di-GMP in *B. subtilis* lysates. Only two transitions are shown in insets to indicate relative abundance of the unique identifier ( $m/z$  691  $\rightarrow$  248 in black) and the most abundant fragmentation product ( $m/z$  691  $\rightarrow$  152 in red).




**FIG. S3. *In vivo* detection of c-di-GMP in knockout strains of PdeH, a c-di-GMP phosphodiesterase.** LC-MS/MS was used to detect c-di-GMP via the MRM transitions  $m/z$  691 → 152 (red),  $m/z$  691 → 540 (blue) and  $m/z$  691 → 248 (black) for c-di-GMP standard (A) and *B. subtilis* extracts from the following strains: (B) wild type; (C)  $\Delta$  *pdeH::kan* lacking a putative c-di-GMP Phosphodiesterase; (D)  $\Delta$  *pdeH::kan, amyE::pdeH* showing active phosphodiesterase complementation and (E)  $\Delta$  *ydaK dgcK dgcW dgcP::tet pdeH::kan* lacking a putative c-di-GMP phosphodiesterase and all possible diguanylate cyclases. Transitions  $m/z$  691 → 152 (red),  $m/z$  691 → 540 (blue) are not unique to c-di-GMP in *B. subtilis* lysates. Only two transitions are shown in insets to indicate relative abundance of the unique identifier ( $m/z$  691 → 248 in black) and the most abundant fragmentation product ( $m/z$  691 → 152 in red).




**FIG. S4. In vitro detection of enzymatic activity of putative *B. subtilis* DGCs.** To assess the activity of putative DGCs in vitro, LC-MS/MS was employed with MRM to detect enzymatic production of c-di-GMP from purified single or dual domain constructs containing GGDEF motifs. All ion peaks indicate production of c-di-GMP in *in vitro* assays. In total, four GGDEF single domain proteins were analyzed - (A) YdaK, (B) DgcK, (C) DgcP and (E) DgcW - as well as two dual domain constructs containing GGDEF and either GAF or PAS domains (D, F). As c-di-GMP co-purifies with the DgcK GGDEF protein exogenously expressed and purified from *E. coli*, uniformly labeled  $^{13}\text{C}$ ,  $^{15}\text{N}$ -GTP was used as a substrate for the DgcK GGDEF enzymatic reactions. For this isotope, the MRM transitions  $m/z$  721 → 162 (red line),  $m/z$  721 → 560 (blue line) and  $m/z$  721 → 263 (black line) were utilized (B), which


corresponds to the  $m/z$  691 → 152 (red),  $m/z$  691 → 540 (blue) and  $m/z$  691 → 248 (black) transitions used in all other cases.




**FIG. S5. Measurement of binding affinities of c-di-GMP to (A) YdaK and (B) DgrA.** At least three titrations were carried out at 25 °C in each case with a single representative titration shown. The measured dissociation constant and standard deviations for c-di-GMP binding to YdaK and DgrA were  $1.1 \pm 0.2 \mu\text{M}$  and  $11.0 \pm 0.4 \text{nM}$ , respectively. Buffer conditions: 10 mM sodium citrate phosphate, 200 mM NaCl, pH 7.5.



**FIG. S6. *B. subtilis* biofilm formation is unaffected by alterations in c-di-GMP signaling.** Strains with deletions or disruptions in any individual or all *B. subtilis* GGDEF protein(s) show no assembly defect in biofilm or pellicle formation assays, indicating c-di-GMP is not required for biofilm production (top two rows). Likewise, overexpression of each individual GGDEF protein does not alter biofilm or pellicle formation. The *epsH::tet* mutant is a control to illustrate a context in which these processes are disrupted.



**FIG. S7. Swarm expansion assays of strains constitutively expressing YdaK or Ykul, potential c-di-GMP receptors, in a background containing elevated c-di-GMP levels (*pdeH*).** Swarming of *B. subtilis* 3610-wild type; DK391, a *pdeH* deletion; NPS265, a constitutive expression strain of *ykuI* in *pdeH* background; and NPS266, a constitutive expression strain of *ydaK* in *pdeH* were shown. YkuI and YdaK do not act as c-di-GMP receptors involved in motility, as each protein does not inhibit motility when expressed in a background containing c-di-GMP (cf. *dgrA* in Fig 9Q). Each point is an average of three replicates.



- |                   |                       |
|-------------------|-----------------------|
| 1. 1Kb DNA ladder |                       |
| 2. WT             | Primer Pair 2928/2931 |
| 3. $\Delta dgcW$  |                       |
| 4. WT             | Primer Pair 2932/2935 |
| 5. $\Delta ydaK$  |                       |
| 6. WT             | Primer Pair 2936/2939 |
| 7. $\Delta dgcK$  |                       |
| 8. WT             | Primer Pair 2924/2927 |
| 9. $dgcP::tet$    |                       |

**FIG. S8. PCR verification for dgc knockout mutants.** Primer pairs for amplification of wild type and mutant sequences are listed on the right.

**Table S1.** *B. subtilis* strains used in this study

Strain	Genotype
3610	
DK391	<i>pdeH::kan</i>
DK392	$\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$ <i>pdeH::kan</i>
DK393	<i>pdeH::kan dgrA::erm</i>
DK404	<i>dgcP::tet pdeH::kan</i>
DK405	$\Delta dgcW pdeH::kan$
DK406	$\Delta ydaK pdeH::kan$
DK407	$\Delta dgcK pdeH::kan$
DS4856	<i>amyE::Physpank-dgcW spec</i>
DS4857	<i>amyE::Physpank-dgcP spec</i>
DS4858	<i>amyE::Physpank-ydaK spec</i>
DS4859	<i>amyE::Physpank-dgcK spec</i>
DS9883	$\Delta dgcW$
DS9289	$\Delta ydaK$
DS9305	$\Delta dgcK$
DS9537	<i>dgcP :: tet</i>
DS9408	$\Delta ydaK \Delta dgcK$
DS9544	$\Delta ydaK dgcP::tet$
DS9545	$\Delta dgcK dgcP::tet$
DS9548	$\Delta ydaK \Delta dgcK dgcP::tet$
DS9884	$\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS079	<i>amyE::Physpank-dgcW spec</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS080	<i>amyE::Physpank-dgcP spec</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS081	<i>amyE::Physpank-ydaK spec</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS082	<i>amyE::Physpank-dgcK spec</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS207	<i>amyE::Physpank-dgcW ΔEAL spec</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS208	<i>amyE::Physpank-dgcK GGGGF mutant spec</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS209	<i>amyE::Physpank-dgcP GGGGL mutant spec</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS215	<i>amyE::Physpank-dgcK GGAAF mutant spec</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS216	<i>amyE::Physpank-dgcP GGAAL mutant spec</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS217	<i>dgrA :: erm mls</i>
NPS218	<i>dgrA :: erm mls</i> , $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS219	<i>amyE::Physpank-dgcP spec</i> , <i>dgrA :: erm mls</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS220	<i>amyE::Physpank-dgcK spec</i> , <i>dgrA :: erm mls</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS221	<i>amyE::Physpank-dgcW ΔEAL spec</i> <i>dgrA :: erm mls</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS224	<i>amyE::Physpank-dgcW PAS-GGAAF ΔEAL spec</i> $\Delta ydaK \Delta dgcK \Delta dgcW dgcP::tet$
NPS233	<i>amyE:: pdeH cat, pdeH::kan</i>
NPS235	<i>amyE::Pconstitutive-dgrA spec, pdeH::kan</i>
NPS236	<i>amyE::Pconstitutive-dgrA spec, pdeH::kan, ΔydaK ΔdgcK ΔdgcW dgcP::tet</i>

NPS247	<i>thrc::Physpank-dgcP mls, amyE::Pconstitutive-dgrA spec, pdeH::kan, ΔydaK ΔdgcK ΔdgcW dgcP::tet</i>
NPS252	<i>thrc::Physpank-<sub>Bs_dgcP</sub>-dcpA mls ,amyE::Pconstitutive-dgrA spec, pdeH::kan, ΔydaK ΔdgcK ΔdgcW dgcP::tet</i>
NPS254	<i>thrc::Physpank-<sub>Bs_dgcP</sub>-cd1420 mls ,amyE::Pconstitutive-dgrA spec, pdeH::kan, ΔydaK ΔdgcK ΔdgcW dgcP::tet</i>
NPS255	<i>thrc::Physpank-<sub>Bs_dgcP</sub>-Atu1297 mls ,amyE::Pconstitutive-dgrA spec, pdeH::kan, ΔydaK ΔdgcK ΔdgcW dgcP::tet</i>
NPS265	<i>amyE::Pconstitutive-YkuI spec, pdeH::kan</i>
NPS266	<i>amyE::Pconstitutive-YdaK spec, pdeH::kan</i>

---

**Table S2 Plasmids used in this study**

Plasmid	Genotype/reference
pAH25	<i>amyE::spec amp</i> (gift from Dr. Amy Camp, Mount Holyoke College)
pAH52	<i>erm amp</i>
pDG1515	<i>tet amp</i> (Guérout-Fleury et al., 1995)
pDG364	<i>amyE cat</i>
pDP150	<i>thrC_Physpank mls</i>
pDP391	$\Omega\Delta dgcW mls amp$
pDP392	$\Omega\Delta ydaK mls amp$
pDP393	$\Omega\Delta dgcK mls amp$
pDP407	<i>ypfA::erm amp</i>
pDR90	<i>amyE::Phyperspac spec amp</i> (gift from Dr. David Rudner, Harvard)
pDR111	<i>amyE intergration vector that contains Physpank, spec and amp</i>
pHis-parallel	N-terminal His-tag expression vector <i>amp</i>
pKB149	<i>amyE_Pconstitutive spec</i>
pMiniMAD	<i>ori<sup>BsTs</sup> mls</i> (Patrick and Kearns, 2008)
pMBP-parallel	N-terminal MBP-tag expression vector <i>amp</i>
pHS001	<i>pHis-parallel with pdeH, amp</i>
pXG075	<i>pHis-parallel with ydaK GGDEF domain, amp</i>
pXG076	<i>pHis-parallel with dgcK GGDEF domain, amp</i>
pXG061	<i>pMBP-parallel with dgcP GGDEF domain, amp</i>
pXG074	<i>pHis-parallel with dgcP GAF-GGDEF domain, amp</i>
pXG077	<i>pMBP-parallel with dgcW GGDEF domain, amp</i>
pXG079	<i>pHis-parallel with dgcW PAS-GGDEF domain, amp</i>
pXG001	<i>amyE::Physpank-dgcW, spec</i>
pXG002	<i>amyE::Physpank-dgcP, spec</i>
pXG003	<i>amyE::Physpank-ydaK, spec</i>
pXG004	<i>amyE::Physpank-dgcK, spec</i>
pXG085	<i>pHis-parallel with dgrA, amp</i>
pXG086	<i>amyE::Physpank-dgcW ΔEAL, spec</i>
pXG087	<i>amyE::Physpank-dgcK GGGGF mutant, spec</i>
pXG088	<i>amyE::Physpank-dgcP GGGGL, spec</i>
pXG090	<i>amyE::Physpank-dgcK GGAAF, spec</i>
pXG091	<i>amyE::Physpank-dgcK GGAAF, spec</i>
pXG092	<i>amyE::Physpank-dgcW GGAAF ΔEAL, spec</i>
pXG093	<i>pHis-parallel with dgrA C4, amp</i>
pXG094	<i>amyE:: pdeH, cat (complementation)</i>
pXG095	<i>amyE::Pconstitutive-dgrA, spec</i>
pXG100	<i>thrC::Physpank-dgcP, mls</i>
pXG101	<i>thrC::Physpank-dgcP, mls</i>
pXG102	<i>thrC::Physpank-dgcP-dcpA, mls</i>
pXG104	<i>thrC::Physpank-dgcP-CD1420, mls</i>
pXG105	<i>thrC::Physpank-dgcP-Atu1297, mls</i>

---

pXG124	<i>amyE::Pconstitutive-ykul, spec</i>
pXG125	<i>amyE::Pconstitutive-ydaK, spec</i>

---

**Table S3 Primers used in this study**

<b>Primers for enzymatic activity assays <i>in vitro</i></b>	
GXH466	YdaK GGDEF domain(Ncol)
GXH460	YdaK GGDEF domain(EcoRI)
GXH467	DgcK GGDEF domain (Ncol)
GXH462	DgcK GGDEF domain(EcoRI)
GXH454	DgcP GGDEF (Ncol)
GXH440	DgcP GGDEF(EcoRI)
GXH465	DgcP GAF-GGDEF (Ncol)
GXH458	DgcP GAF-GGDEF(EcoRI)
GXH453	DgcW GGDEF (Ncol)
GXH471	DgcW GGDEF (EcoRI)
GXH464	DgcW PAS-GGDEF (stul)
GXH468	DgcW PAS-GGDEF (SpeI)
GXH480	PdeH (Ncol)
GXH481	PdeH (EcoRI)
GXH482	DgrA(Ncol)
GXH483	DgrA (EcoRI)
GXH513	DgrA (EcoRI)
<b>Primers for overexpression/ constitutive expression <i>in vivo</i></b>	
GXH301	dgcWF (Sall)
GXH302	dgcWR (NheI)
GXH303	dgcPF(NheI)
GXH304	dgcPR(SphI)
GXH305	ydaKF(NheI)
GXH306	ydaKR(SphI)
GXH307	dgcKF(HindIII)
GXH308	dgcKR(NheI)
GXH516	dgrAF (SphI)
GXH517	dgrAR (BamHI)
GXH532	dgcP (HindIII)
GXH533	dgcP (SphI)
GXH534	dgcP(-60~+3)
GXH535	dgcP (-60~+3)
GXH536	dgcP (-60~+3)
GXH537	dgcP (-60~+3)
GXH538	dgcP (-60~+3)

GXH539	dgcP (-60~+3)	gacctcgccccaccgaatttagcttgcatt tggtaaacttttaggtataaaaacatggcttagcattagatattca
GXH540	dcpA (NheI)	actcgccccatct cgttccaccgaatttagcttgcattgctggcgtgaggaagccaaa
GXH521	dcpA (SphI)	aaggtaag tggtaaacttttaggtataaaaacatggcttagcttaaagaaatt
GXH542	CD1420 (NheI)	tttttaagaactttccagga gacctcgccccaccgaatttagcttgcattgcatgtacaagttaaaa
GXH543	CD1420 (SphI)	aaagaaaagataatttaatt tggtaaacttttaggtataaaaacatggcttagcacggcgagagt
GXH544	Atu1297 (NheI)	tctggtttgtac cgttccaccgaatttagcttgcattgcatgcgagaggctgcacaaacagtc
GXH531	Atu1297 (SphI)	gtggtaa
GXH583	ykul (SphI)	ggg gcatgc gtgcgtataatcagacaaagatagagaagc
GXH584	ykul (NheI)	ggg gcttagc aaacggccttcagccgttaatc
GXH585	ydaK(SphI)	ggg gcatgc cacgcattcattgacaatctgctg
GXH586	ydaK(NheI)	ggg gcttagc aatagaagcatcatgacgcatacg

## Primers for gene knockouts and complementation *in vivo*

2006		cgccattcgccaggctgcag
2007		ctcctgcacacacattatgccacacacctgttag
2928	dgcWUF (EcoRI)	aggaggaattcatctgcaaaaacaacgcaca
2929	dgcWUR (Xhol)	ctcctctcgagatattccatcgccatttccat
2930	dgcWDF (Xhol)	aggagctcgaggtgattgccgaaggtgtgg
2931	dgcWDR (BamHI)	ctcctggatcccagggtataggccttcgt
2932	ydaKUF (EcoRI)	aggaggaattcgtcttgaagacatacaatatg
2933	ydaKUR (Xhol)	ctcctctcgagcagacacccttgtattgtc
2934	ydaKDF (Xhol)	aggagctcgagggaaagtatgtgtcgcttacg
2935	ydaKDR (BamHI)	ctcctggatccctctgagctgtttcgccac
2936	dgcKUF(EcoRI)	aggaggaattctcggtgaagtccgtctagctc
2937	dgcKUR (Xhol)	ctcctctcgagtagactagccttcttaacagg
2938	<i>dgcK</i> DF (Xhol)	aggagctcgagcttgccgatcaaatgcttac
2939	<i>dgcK</i> DR (BamHI)	ctcctggatcctcgggattgctgagctgac
3037	<i>dgcP</i> UP F 3 (BamHI)	aggagggatccgtctgcttattcgaccatag
3038	<i>dgcP</i> UP R 3 (PstI)	ctcctctcgaggcacgcaagatggaaacgc
3039	<i>dgcP</i> DN F 3 (EcoRI)	aggaggaattcacgtacggccatcagactg
3040	<i>dgcP</i> DN R 3 (Xhol)	ctcctctcgagcagaattgtgtccgatttc
GXH489	<i>dgrA</i> UPF (EagI)	aggagccgcggAACAGGAAGCAAAACAAATTG
GXH490	<i>dgrA</i> UPR (BamHI)	ctcctggatccgtacatttctccaatctctatc
GXH491	<i>dgrA</i> DNF (Xhol)	aggagctcgagcaggcttgctcaatactgc
GXH492	<i>dgrA</i> DNR (KpnI)	ctcctggatccgtacattggcagcacatg
3428	<i>pdeH_kan</i> ITA UP F	ggaaagcgtttaatatcccg

3429	<i>pdeH_kan</i> ITA UP R	caattcgcctatagtgagtcgtacaaacaccctattgatttac
3430	<i>pdeH_kan</i> ITA DN F	ccagctttgtcccttagtgagatggacgcaaatgattgcgg
3431	<i>pdeH_kan</i> ITA DN R	ggacattaaaggacagcagg
GXH514	<i>pdeH</i> complementation F	tgataagctgtcaaacatgagaattcgaaagaaagtctaccgca
GXH515	<i>pdeH</i> complementation R	ttattaatcagtcc atggtagcgcaccggcgctcaggatcattgcggtggtcagagga ccgc

**Primers for DGC mutants *in vivo***

GXH484	dgcW <i>in vivo</i> truncation	cctc gctagc ttaagaatagtatctgtattgcctttg
GXH485	dgcK GGGGF mutant	gatcctgccgcgtcgatcgccgggtggcggtttgcgtgcctcg ccgaactg
GXH486	dgcK GGGGF mutant	cagttcggcaggagcacggcaaaaccgccaccgccatccga gcggcaggatc
GXH487	dgcP GGGGL mutant	cggtgcccgtggggaggaggaggactggcgattattgccaa atgtgccc
GXH488	dgcP GGGGL mutant	cggcacattggcaaataatgcgcgtcctcctccccagcg ggcacccg
GXH495	dgcK GGAAF mutant	gatcctgccgcgtcgatcgccgggtggcgctttgcgtgcctcg ccgaactg
GXH496	dgcK GGAAF mutant	cagttcggcaggagcacggcaaaagcggcaccgccatccga gcggcaggatc
GXH497	dgcP GGAAL mutant	cggtgcccgtggggaggaggccgcctggcgattattgccaa atgtgccc
GXH498	dgcP GGAAL mutant	cggcacattggcaaataatgcgcaggcggtcctccccagcg gggcacccg
GXH499	dgcW GGAAF ΔEAL	ccgtcttggcggtgctgcatttatttatataac
GXH500	dgcW GGAAF ΔEAL	gttaataataataatgcagcaccccaagacgg